Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864487 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib
A Phase 1 study, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00864487 is a Phase 1 study that has completed, run by Puma Biotechnology. The registered enrollment target is 24 participants.
The verdict
NCT00864487, a Phase 1 study, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether co-administration of rifampin with neratinib has an effect on the pharmacokinetics (how the body absorbs, distributes, metabolizes and/or excretes) of neratinib.
Interventions
- DRUG Neratinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00864487
The ClinicalTrials.gov registry entry for NCT00864487 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neratinib is the first listed.
NCT00864487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00864487 about?
NCT00864487 is a clinical study titled "Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib". The purpose of this study is to examine whether co-administration of rifampin with neratinib has an effect on the pharmacokinetics (how the body absorbs, distributes, metabolizes and/or excretes) of neratinib.
What is the current status of trial NCT00864487?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-04. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00864487?
The interventions under investigation include: Neratinib (DRUG).
Who is sponsoring clinical trial NCT00864487?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.